Compare BigBearai Holdings Inc (BBAI) vs Summit Therapeutics Inc (SMMT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BigBearai Holdings Inc vs Summit Therapeutics Inc — how do they compare? BigBearai Holdings Inc trades at $3.26 (market cap $1.60B), while Summit Therapeutics Inc trades at $15.25 (market cap $12.06B). The key difference: Summit Therapeutics Inc is far larger — about 7.5× BigBearai Holdings Inc's market cap. Which is the better fit depends on your goals.
| BBAI | SMMT | |
|---|---|---|
Market Cap | $1.60B | $12.06B |
Sector | Technology | Health |
52-Week High | $8.91 | $26.98 |
52-Week Low | $2.61 | $12.55 |
Enterprise Value | $1.30B | $11.39B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BigBear.ai (BBAI) trades at $3.25, up 0.62% with a bullish technical signal. The company reported Q2 2026 revenue growth of 13% and margin expansion but missed EPS expectations. With a P/S ratio of 11.31 and negative profitability metrics, the stock faces fundamental challenges despite recent contract wins and product innovation in defense AI solutions.
Outlook remains cautious with persistent losses and cash burn offset by government contract momentum. Investment opportunity lies in defense AI specialization, while risks include execution challenges and competitive pressures. Analyst consensus shows 75% hold rating, reflecting balanced skepticism about near-term profitability.
Summit Therapeutics (SMMT) trades at $15.23, up 2.42% today, with a bullish technical signal and strong analyst consensus. The stock shows mixed earnings performance but benefits from positive news on ivonescimab's regulatory progress and clinical expansions. Despite negative profitability metrics, investor sentiment is buoyed by a high price target of $38.00 and recent partnership announcements in cancer drug development.
Outlook hinges on FDA approval for ivonescimab by November 2026, offering significant upside if successful. Risks include cash burn, ongoing losses, and fiduciary investigations. The stock presents a high-risk, high-reward opportunity for speculative investors betting on clinical successes.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About BigBearai Holdings Inc
BigBearai Holdings Inc is a specialized provider of AI-driven decision intelligence solutions, primarily serving the U.S. defense, intelligence, and national security communities. It operationalizes complex data into actionable insights through its core modules—Observe, Orient, and Dominate—to support mission-critical operations and logistics.
Read more on BBAI →About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →
